Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.
Egis World
Egis' products are sold to 100 countries.
Egis Pharmaceuticals PLC acquired Sinuforte from Hartington Business S.L. Under the agreement Egis receives all rights related to the product, a nasal spray indicated for the treatment of sinusitis and other inflammatory diseases of the paranasal sinuses. The company seeks to ensure its growing presence in major export markets through organic growth and targeted acquisitions. More
Egis keeps growing in OTC markets via acquisition
Egis Pharmaceuticals PLC has acquired Sorbifer’s product rights from AstraZeneca. The transaction reinforces Egis’ position on its key markets.
Egis expands gynecological and dermatological portfolio in Russia
Egis Pharmaceuticals expands portfolio thus improves Russian people’s access to its high quality, EU manufactured therapies.
Other channels
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
In the 2022/2023 business year, the company’s product portfolio consisted of 653 products
In the 2022/2023 business year, we spent EUR 48 million on research and development
Healthcare and sharing knowledge are in the heart of our CSR activities
Our highlighted past and future events you shouldn't miss
Quick news
Your browser is out of date. Please, use an updated version!